Related Experiment Video
Updated: Jul 9, 2026

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers
Published on: October 24, 2019
Quality control of Actinium-225 radiopharmaceuticals: Current challenges and solutions in Malaysia
Z Ashhar1, M F Fadzil2, M A Said3
1Sabah Women and Children Hospital, Nuclear Medicine Department, Locked Bag No. 187, Kota Kinabalu, Sabah, Malaysia.
Abstract:
Development of Prostate Specific Membrane Antigen (PSMA)-targeted radiopharmaceuticals for theranostics has changed the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC). The emerging use of [225Ac]Ac-PSMA-RLT has been effective and safe for the treatment of mCRPC. Nevertheless, challenges with the nuclear recoil of [225Ac]Actinium radionuclides, which may release the daughter radionuclide from the radiopharmaceutical and lead to unnecessary irradiation of other organs, poses threats such as organ dysfunction. Therefore, this short communication aims to highlight the current situation in Malaysia and explain the solutions by using a risk-based approach analysis for the inhouse preparation.
Related Concept Videos
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical Poisoning: Treatment Strategies
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
